686747-95-5

Upstream product

• 683210-69-7 (3aR,4R,7R,7aR)-5-(4'-benzyloxybenzenesulfonyl)-7-hydroxy-2,2-dimethylhexahydro[1,3]dioxolo[4,5-c]-4-carboxylic acid methyl ester 
• 686747-91-1 (3aR,6R,7R,7aR)-5-(4-Benzyloxy-benzenesulfonyl)-7-methoxy-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridine-6-carboxylic acid methyl ester 
• 686747-90-0 (3aR,6R,7R,7aS)-5-(4-Benzyloxy-benzenesulfonyl)-7-hydroxy-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridine-6-carboxylic acid methyl ester 
• 686747-93-3 (3aR,6R,7R,7aR)-5-(4-But-2-ynyloxy-benzenesulfonyl)-7-methoxy-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridine-6-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Synthesis and biological activity of selective azasugar-based TACE inhibitors

A series of azasugar-based hydroxamic acid derivatives bearing 2R,3R,4R,5R-configuration is described. Compound 4c with 4,5-O-acetonide group showed excellent in vitro potency against TACE, with high selectivity over MMP-1 and moderate selectivity over MM